210 related articles for article (PubMed ID: 20872084)
1. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.
Nasir BS; Dozois EJ; Cima RR; Pemberton JH; Wolff BG; Sandborn WJ; Loftus EV; Larson DW
J Gastrointest Surg; 2010 Dec; 14(12):1859-65; discussion 1865-6. PubMed ID: 20872084
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
Syed A; Cross RK; Flasar MH
Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
[TBL] [Abstract][Full Text] [Related]
4. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.
Cullen G; Vaughn B; Ahmed A; Peppercorn MA; Smith MP; Moss AC; Cheifetz AS
Inflamm Bowel Dis; 2012 Apr; 18(4):691-6. PubMed ID: 21648022
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
7. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Allez M; Vermeire S; Mozziconacci N; Michetti P; Laharie D; Louis E; Bigard MA; Hébuterne X; Treton X; Kohn A; Marteau P; Cortot A; Nichita C; van Assche G; Rutgeerts P; Lémann M; Colombel JF
Aliment Pharmacol Ther; 2010 Jan; 31(1):92-101. PubMed ID: 19709098
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
13. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
Patil SA; Rustgi A; Langenberg P; Cross RK
Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
[TBL] [Abstract][Full Text] [Related]
15. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
Danese S
Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
[No Abstract] [Full Text] [Related]
16. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.
Desai A; Zator ZA; de Silva P; Nguyen DD; Korzenik J; Yajnik V; Ananthakrishnan AN
Inflamm Bowel Dis; 2013 Feb; 19(2):309-15. PubMed ID: 22605668
[TBL] [Abstract][Full Text] [Related]
17. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
Schreiber S
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
[TBL] [Abstract][Full Text] [Related]
18. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
Rubin DT; Uluscu O; Sederman R
Inflamm Bowel Dis; 2012 Dec; 18(12):2225-31. PubMed ID: 22359399
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.
Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
Aliment Pharmacol Ther; 2013 Jan; 37(2):214-24. PubMed ID: 23190161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
